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A B S T R A C T
Although the role of angiogenesis in tumor progression and response to treatment is generally well-characterized, for
neuroblastomas clinical data regarding the contribution of angiogenesis and its predictive capacity remain unclear. The
aim of this study was to evaluate whether tumor vascularity in the combination with expression of vascular endothelial
growth factor (VEGF) represent prognostic factors for patients with neuroblastoma. Immunohistochemistry using anti-
-CD34 and anti-VEGF antibodies was used to analyze paraffin-embedded primary tumor tissues from 56 patients diag-
nosed with neuroblastoma. Tumor vascularity was estimated by calculating the tumor vascular volume fraction (TVVF),
and VEGF expression was determined using semi-quantitative scoring. Statistical analyses including multivariate ana-
lysis were performed and compared with these two factors. Tumor vascularity had impact on survival of high VEGF ex-
pression neuroblastoma patients. Combination of high VEGF expression and TVVF value 5% was independent predic-
tor of overall survival (p-value =0.0041, odds ratio (OR) (95%CI)=8.67 (1.99–37.69) by the Cox proportional hazards
model). This study revealed for the first time a group of extremely high-risk neuroblastoma with both high VEGF expres-
sion and poor vascularity. For these patients reduced rates of survival were observed (37% vs. 92.5%) (p<0.0001). These
patients did not experience a significant improvement following hematopoietic stem cell transplantation, and could be
candidates for receiving novel therapies. These results indicate the importance of the mutual relationship between tumor
vascularity and VEGF, because it gives better insight into the prognosis of patients with neuroblastoma.
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Introduction
Angiogenesis plays an important role in the progres-
sion and metastasis of many types of malignant tumors.
For neuroblastoma, this pediatric malignancy is associ-
ated with a broad spectrum of clinical behavior, and the
extent of angiogenesis present appears to affect the tu-
mor's phenotype1. The clinical heterogeneity and embry-
onal origin of this disease also suggest that regulation of
neovascularization is complex2. Various studies have con-
firmed that a positive correlation exists between tumor
microvascular density and an aggressive tumor pheno-
type in cases of neuroblastoma3,4. However, other studies
did not find that vascular parameters of neuroblastoma
predicted patient survival rates5,6, and even found that
low vascular density was asocciated with short survival7.
The prognostic value of microvascular density has
been examined for different types of cancer. Most of
these studies have reported a positive correlation be-
tween tumor vascularity and tumor recurrence8–20. How-
ever, other reports did not find a positive association be-
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tween increased tumor vascularity and reduced survival,
which brings into question the clinical utility of tumor
angiogenesis21–27.
VEGF is an endothelial cell-specific mitogen that is
one of the most important stimulators of tumor angio-
genesis and tumor growth28,29. Furthermore, previous
studies have demonstrated that expression of VEGF cor-
relates with a high-risk phenotype in neuroblastomas28,30–33.
Correspondingly, our previous study identified VEGF ex-
pression as an important biological marker for neuro-
blastomas and it could be used to identify high-risk
neuroblastoma patients in combination with tumor stage
and other relevant risk factors34.
Given that the mechanisms of tumor angiogenesis are
still enigmatic, and relationship between VEGF and tu-
mor angiogenesis in neuroblastoma still unexplored, tu-
mor vascular volume fraction (TVVF) was calculated in
relation to VEGF expression for cases of neuroblastoma.
Furthermore, these factors were evaluated in relation to
the prognosis of the neuroblastoma patients analyzed.
Materials and Methods
Neuroblastoma tissue samples (n=56) were obtained
from the archives of the Institute of Pathology, School of
Medicine, University of Zagreb, Croatia for patients who
had undergone treatment at the Department of Hema-
tology and Oncology of Children’s Hospital Zagreb (Zag-
reb, Croatia) between 1995 and 2008. Clinical staging
was classified according to The International Neuro-
blastoma Staging System (INSS)35,36. Patients were di-
vided into two groups based on their stage of disease. The
»low stage« group included patients with stage 1, 2, or 4s
neuroblastoma, and the »high stage« group included pa-
tients with stage 3 or 4 neuroblastoma. Histopathological
grading was classified according to the Shimada System
and Shimada Age-based Pathologic Classification37,38. All
of the histological samples were reevaluated and received
new grading (SS). Patients with stage 1, 2, or 4s disease
(N=19) were treated with surgery alone, or surgery and
moderate-dose chemotherapy. Alternatively, stage 3 and
stage 4 patients (N=37) were treated with surgery in
combination with intensive, multi-agent chemotherapy
with or without radiotherapy and/or metaiodobenzyl-
guanidine (MIBG) therapy. In addition, 14 patients with
advanced disease, and 3 patients with localized disease
with N-myc amplification, received megatherapy (i.e.,
myeloablative chemotherapy) followed by autologous or
allogeneic hematopoietic stem cell transplantation. Since
hematopoietic stem cell transplantation for high-risk pa-
tients was started in 1999, high-risk patients either recei-
ved, or did not receive, stem cell transplantation (Table 1).
Following surgery, specimens were fixed in 4% buf-
fered formalin for at least 24 h, then were embedded in
paraffin, and stored at room temperature until sectioned.
Serial sections (4–5 mm) were cut and adhered onto mi-
croscope slides. Paraffin was removed from the sections
using xylene and the samples were rehydrated.
CD 34 immunohistochemical analysis
Murine CD34 monoclonal antibody (Dako, Glostrup,
Denmark) was used at a dilution of 1:50, and was incu-
bated with sections for 30 min at room temperature. Sec-
tions were then incubated with peroxidase-conjugated
polymers linked with an appropriate secondary antibody
(Envision-Detection System, Dako, Glostrup, Denmark).
Antibody binding was visualized using 3, 3-diamino-
benzidine (DAB) chromogenic solution. Negative con-
trols were included and were incubated with Tris-buf-
fered saline (TBS) instead of primary antibody.
Low power field screening of immunohistochemically
stained slides was used to identify areas of highest vascu-
larization (»hot spots«). Visible necrosis and calcifica-
tions were excluded. Image analysis was performed on 3
medium power fields using a 10x objective, and these
fields were imaged using an OlympusBX microscope and
Sony 3 chip video camera. Images were then converted to
gray scale using a picture archiving and communication
system (PACS) (ISSA, VAMSTECH, Zagreb, Croatia).
TVVF was measured as the percentage of stained endo-
thelial area (vascular area) relative to the entire ana-
lyzed area (image area). Quantitative analysis was per-
formed using the Electronic Automated Measurement
User System (EAMUSTM, DiagnomX GmbH, Germany)
(http://www.diagnomx.eu/portal/home.php).
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Abbreviations: S, surgery; CTH, chemotherapy; MIBGT, metaio-
dobenzylguanidine therapy; BMT, bone marrow transplant; RT,
radiotherapy
VEGF immunohistochemical analysis
Sections were incubated in 3% hydrogen peroxide for
5 min, then with VEGF-specific mouse monoclonal IgG
(dilution 1:25; Dako, Glostrup, Denmark) for 30 min at
room temperature. Bound antibodies were detected us-
ing a secondary antibody detection kit (LSAB+kit, Dako,
Glastrup, Denmark) and visualized using DAB. Sections
were also counterstained with Mayer’s hematoxylin and
dehydrated before being mounted for analysis. Negative
controls were included and were incubated with Tris-
-buffered saline (TBS) instead of primary antibody. For
positive controls, sections of colon carcinoma were used.
Staining of VEGF was semi-quantitatively analyzed
using a scoring system described in Table 2. Briefly, the
percentage and intensity of stained tumor cells were de-
termined and scored. When these two sets of scores were
added together, specimens were then classified as weak
(0–2) or strong (3–7).
Statistical analysis
Descriptive statistics and 95% confidence intervals
(CI) were used. Data distribution was analyzed using the
D’Agostino-Pearson test. According to the type of distri-
bution, an appropriate parametric, or an equivalent non-
-parametric, test was performed. Spearman’s coefficient
of rank correlation (rho) was determined to assess the
correlation between VEGF scores and TVVF. The cutoff
value for determining low vs. high VEGF expression
scores, as well as low vs. high TVVF scores, was deter-
mined from an analysis of receiver operating characteris-
tic (ROC) curve39. The relationship between VEGF ex-
pression, tumor vascularity, gender, age, tumour localisa-
tion, stage, histology and survival was estimated by ap-
plying the Fisher’s exact test. Overall survival (OS) was
defined as the interval between the time of established
diagnosis and patient’s death. Univariate analysis of OS
was performed as outlined by Kaplan and Meier40. Statis-
tical significance of differences in survival between the
patient groups was estimated using the log-rank test.
The Cox proportional hazards model was used for multi-
variate analysis to determine independent predictors of
overall survival. Differences were considered significant
at p<0.05. Statistical analyses were performed using
MedCalc version 10.4 (MedCalc Software, Mariakerke,
Belgium).
Results
Characteristics of neuroblastoma patients are listed
in Table 1. The mean patient age was 35.5 months
(range: 2 months to 12 years), the median patient fol-
low-up time was 27 months (range: 1.0–180.0 months),
and the overall survival rate was 62.5%. Overall survival
rates were calculated at 24 months.
VEGF expression
Immunohistochemical staining was used to detect
VEGF expression (Figures 1a-c). Consistent with a previ-
ous study that also analyzed these sections, VEGF stain-
ing was detected in 54/56 (96.4%) of the tumor samples34.
The distribution of VEGF scores was normal. Using ROC
curve analysis, a cut off value of >2 (sensitivity 100.0%,
specificity 33.3%) was established, and tumors were dis-
tinguished as having high (score: 3–7) or low (score: 0–2)
levels of VEGF expression. A total of 44 (78.6%) and 12
(21.4%) specimens were associated with each group, re-
spectively (Table 3). A significant correlation between
the VEGF scores and tumor stage was identified (P=
0.002, rho 0.40)34.
Tumor vascularity
CD34 immunohistochemical slides were shown on
Figures 1d-e.The distribution of TVVF values was not
normal. The median TVVF value was 2.5%, while the
lowest and highest TVVF values were 0.016% and 11.83%,
respectively. Using ROC curve analysis, a cut off value of
5 (sensitivity 90.0%, specificity 41.7%) was established,
and tumors with high (>5% TVVF) vs. low (5% TVVF)
levels of vascularity were identified. Overall, a total of
39/56 (69.6%) cases were observed to have low levels of
tumor vascularity, and 17/56 (30.4%) cases exhibited
high levels of vascularity (Table 3). No correlation be-
tween tumor vascularity and tumor stage was observed
(p=0.98, rho 0.002).










<1% 0 Weak 1
1–25% 1 Moderate 2






Total score* = Score1 + Score2
TABLE 3







Low (0–2) 12 (21.4%) 12/0
High (3–7) 44 (78.6%) 23/21
Tumor vascularity
Low (TVVF 5%) 39 (69.6%) 21/18
High (TVVF >5%) 17 (30.4%) 15/2
*Tumor vascular volume fraction=100 ´ vascular area/image area
Correlation between VEGF score and TVVF
A significant positive correlation between VEGF sco-
res and tumor vascularity (TVVF) was identified using
Spearman’s coefficient of rank (rho=0.347, p=0.010).
High VEGF expression also correlated with higher TVVF
values (median 2.89% vs. 1.19%), although this differ-
ence was not statistically significant according to the
Mann-Whitney test.
Survival analysis
The overall survival rate (OSR) for patients with high
vs. low levels of VEGF expression was 54.5%, and 100%,
respectively. Furthermore, the tumors of deceased patients
were associated with higher levels of VEGF expression
compared to surviving patients (p=0.0046, Figure 2a).
For patients with low tumor vascularity (TVVF5%)
vs. high tumor vascularity (TVVF>5%), their OSRs were
53.8% and 88.0%, respectively. Moreover, the difference
in tumor vascularity values for surviving vs. deceased pa-
tients had a p-value of 0.056 by Mann-Whitney test. For
TVVF values, those of the deceased patients were lower
than those of the living patients. The median values for
these two groups were 1.19% and 2.83%, respectively.
Furthermore, a greater number of deceased patients
were associated with tumors characterized by TVVF val-
ues 5% compared to surviving patients associated with
TVVF values >5% (p=0.0162, Figure 2b).
Kaplan-Meier survival curves were generated based
on high vs. low VEGF expression (Figure 3a), and for
TVVF values >5% or 5% (Figure 3b). Survival rates for
patients with low VEGF expression (p=0.0053) and high
TVVF values (p=0.0227) were found to have a better
outcome. Furthermore, tumor vascularity did not impact
the survival of patients with low VEGF expression, since
all of these patients survived.
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Fig. 1. VEGF and CD34 immunohistochemical staining in neuroblastoma pathohistological sections. Representative image of a section
that received a) a low VEGF expression score (low grade intensity and 1–25% tumor cell positivity); b) a high VEGF expression score
(high grade intensity and 25–50% tumor cell positivity); c) a high VEGF expression score (moderate grade intensity and 75–100% tumor
cell positivity). (a–c) Objective = 40X; d) Immunohistochemical staining of endothelial cells in a neuroblastoma section detected using
anti-CD34 antibody. (d) Objective=4X; (e) Objective=10X.
Fig. 2. Relationship between high vs. low VEGF expression and
TVVF values for surviving vs. deceased patients. a) According to
Fisher’s test, a p-value of 0.0046 was associated with VEGF ex-
pression levels; and b) a p-value of 0.0162 was associated with
TVVF values > or 5%. Expression of VEGF and TVVF values
were significant prognostic factors.
The impact of tumor vascularity on the survival
of neuroblastoma patients with high VEGF
expression
For tumors with high VEGF expression and TVVF
values 5% vs. >5%, the OSRs were 37.9% and 86.6%, re-
spectively. Moreover, this difference was significant by
Fischer’s exact test (p=0.0034) and by Kaplan-Meier
analysis (p=0.0032, Figure 4). Deceased patients were
associated with significantly lower TVVF values (median
1.19%) than surviving patients (median 5.02%) by Mann-
-Whitney test (p=0.0063).
Correlation between VEGF score and TVVF
in surviving and deceased patients
Using Spearman’s coefficient of rank, TVVF values
were also found to correlate with VEGF expression in
surviving patients (p=0.003), yet not for deceased pa-
tients (p=0.185).
High VEGF expression and low tumor vascularity
as a complex variable
Survival of patients with neuroblastoma was also ana-
lyzed with VEGF expression and tumor vascularity eval-
uated as a complex variable (Figures 5 a,b). When pa-
tients with high levels of VEGF expression (score >2)
and low vascularity scores (TVVF 5%) were evaluated
using this approach, an OSR of 37.9% was identified,
compared to an OSR of 92.6% associated with all other
patients (p=0.000018 by Fischer’s test and p<0.0001 by
log-rank test).
To further examine characteristics of this subset of
patients, they were evaluated according to age, tumor
stage, histology, and tumor localization (Table 4). As a re-
sult, a greater number of advanced stage disease patients
were identified (82.8% vs. 48.1%) (p=0.0142) that also
were associated with an unfavorable histology (86.2% vs.
59.2%) (p=0.0334). Other differences were not statisti-
cally significant. Patients with advanced stage tumors
(stage 3 and 4) also had their OSR evaluated in relation
to high levels of VEGF expression and low tumor vas-
cularity as a complex variable (Figure 6a), and in relation
to hematopoietic stem cell transplantation (HSCT) (Fig-
ure 6b). An OSR of 29.0% was identified in comparison
with other advanced stage patients (OSR 84.6%, p=
0.0019), and HSCT was not found to improve their sur-
vival significantly (p=0.11).
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Fig. 3. Kaplan-Meier survival curves for high vs. low VEGF ex-
pression and TVVF values. a) The blue line represents patient
survival associated with low VEGF expression, and the red line
represents patient survival associated with high VEGF expres-
sion. b) The blue line represents patient survival associated with
a TVVF value >5%, and the red line represents patient survival
associated with TVVF values 5%. Both VEGF expression and
TVVF were significant prognostic factors.
Fig. 4. The impact of tumor vascularity on the survival of pa-
tients with high levels of VEGF. a) Using Fischer’s exact test, sur-
viving (red) vs. deceased (blue) patients with high levels of VEGF
were compared with respect to TVVF values (>5% vs. 5%); b) A
Kaplan-Meier survival curve represents the patients with high
levels of VEGF expression that were associated with TVVF val-
ues >5% (blue) and 5% (red). A significant difference in patient
survival for patients with high levels of VEGF expression accord-
ing to different tumor vascularity was observed.
Fig. 5. The impact of VEGF expression and tumor vascularity as
a complex variable on survival. a) Using Fischer’s exact test, pa-
tient survival was evaluated for high VEGF expression and low
TVVF values for both deceased (red) and surviving (blue) pati-
ents; b) Kaplan-Meier survival curve shows the survival of pa-
tients with high VEGF expression and low TVVF values (red li-
ne) vs. other patients (blue line). The combination of VEGF expres-
sion and TVVF values were found to be significant predictors of
patient survival.
In order to determine independent predictors of over-
all survival, multivariate analysis was performed. The
full Cox proportional-hazards regression model (Step-
wise method) was statistically significant (p<0.001), indi-
cating that this model was able to distinguish between
survival and non-survival. As shown in Table 5, two pre-
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TABLE 4
CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH HIGH LEVELS OF VEGF* AND LOW LEVELS OF TUMOR
VASCULARITY** EVALUATED AS A COMPLEX VARIABLE
Characteristics
High VEGF & All other patients Fischer’s test
Low tumor vascularity p-value
N (%) N (%)
Total number 29 27
Gender
Male 18 62.1% 17 63.0% 1.00
Female 11 37.9% 10 37.0%
Age
18 months old 7 35% 13 48.2% 0.09
>18 months old 22 65% 14 51.8%
Histological subtype
Stroma-rich 5 17.2% 11 40.8% 0.07
Stroma-poor 24 82.8% 16 59.2%
Histology
Favorable 4 13.8% 11 40.8% 0.03
Unfavorable 25 86.2% 16 59.2%
Stage
Low 5 17.2% 14 51.9% 0.01
High 24 82.8% 13 48.1%
Abdomen
Yes 24 82.7% 19 70.3% 0.34
No 5 17.3% 8 29.7%
Status
Surviving 11 38.0% 25 92.7% 0.000018
Deceased 18 62.0% 2 7.3%
*VEGF score >2
**Tumor vascular volume fraction 5%
TABLE 5
COX PROPORTIONAL-HAZARDS REGRESSION MODEL
(STEPWISE METHOD)* FOR NEUROBLASTOMA PATIENTS
OVERALL SURVIVAL
Covariate p OR** 95% CI***of OR




0.0041 8.6741 1.9961 to 37.6941
*Overall model fit c2=28.4461 p<0.0001
Abbreviations: **Odds ratio; *** Confidence interval
**** VEGF expression score >2 and VVF 5.0%
Variables not included in the model: age, localisation, histology,
transplantation
Fig. 6. Kaplan-Meier overall survival curves for advanced stage
patients (stage 3 and 4). a) The presence of high VEGF expres-
sion (score >2) and low tumor vascularity (TVVF 5%) were eva-
luated as a complex variable (red line), and these patients were
associated with significantly shorter survival periods (p=0.0019)
than all others (blue line); b) Patients that received (red line) or
did not receive (blue line) HSCT were evaluated, and HSCT did
not significantly improve patient survival (p=0.11).
dictor variables significantly affected the model, high dis-
ease stage (p=0.0394, OR=8.4436, 95%CI 1.1211 to
63.5956), and high VEGF expression with low tumor
vascularity as a complex variable (p=0.0041, OR 8.6741,
95%CI 1.9961 to 37,6941).
Discussion
In this study low tumor vascularity in high VEGF ex-
pression tumors were associated with a lower OSR. To
our knowledge, this is the first clinical study to evaluate
the impact of differences in vascularity using image anal-
ysis to determine the prognosis of high VEGF expression
in neuroblastoma patients. Based on a search of the liter-
ature currently available, our study represents the first
analysis of vascular volume fraction as a measure of tu-
mor angiogenesis in neuroblastoma patients. Canete et
al. (2000) used a similar method, however, they examined
other vascular variables5. For differences in TVVF values
for surviving vs. deceased patients estimated using the
Mann-Witney test, near statistical significance was ob-
served. Furthermore, the TVVF values associated with
the group of deceased patients were lower than the
TVVF values attributed to the surviving patients. Low
tumor vascularity (TVVF 5%) was also significantly as-
sociated with a bad prognosis, and characterized patients
having a shorter survival. Although this result was un-
predictable, it may be due to the high ratio of patients
with unfavorable biologic and clinical features that were
included in this study. We hypothesize that tumors with
high VEGF expression along with low levels of vas-
cularity undergo an up-regulation of glycolysis and acid
resistance, which results in a powerful growth advantage
to promote unconstrained proliferation and invasion. In
contrast, high vascularity (TVVF >5%) detected in the
neuroblastoma cases examined was associated with a
good prognosis, and appeared to indicate that these tu-
mors were well-oxygenated. Although measurements and
markers of angiogenesis cannot be used as surrogate
measures of tumor hypoxia, we hypothesize that patients
with high tumor vascularity experience a sufficient de-
gree of tumor oxygenation and efficiency of tumor vas-
cularization for blood delivery, which would have a sig-
nificant impact on the success of treatment. Our results
are contrary to those of other studies where a positive
correlation between tumor angiogenesis (microvascular
density) and unfavorable outcome were observed for
neuroblastoma patients. For example, Meitar et al. (1996)
found that a high tumor vascular index value was an in-
dependent, adverse prognostic factor in neuroblastoma3.
In contrast, vascular parameters were not predictive of
survival for neuroblastoma patients in a study by Canete
at al. (2000) and Noguera et al. (2009)5,6. Izycka-Swiesze-
wska et al. (2007) found that lower vascular density and
pathologic-type angiogenesis were associated with a shor-
ter survival for neuroblastoma patients7. The differences
in these results could be attributed to the different meth-
ods of measurement used, differences in the evaluation
of biological readouts, and differences in the ratios of pa-
tients with favorable vs. unfavorable biological and clini-
cal features.
In this study tumors with high levels of VEGF expres-
sion were initially predicted to have greater tumor vas-
cularity compared with tumors expressing low levels of
VEGF. However, the difference between these two groups
was not significant. Tumor vascularity also had no de-
tectable impact on the survival of patients with low levels
of VEGF expression, since all of these patients survived.
In contrast, deceased patients with high levels of VEGF
expression had significantly lower TVVF values com-
pared to surviving neuroblastoma patients with high lev-
els of VEGF expression. This result indicates that it is
important to discriminate the angiogenesis associated
with low vs. high VEGF expression, as well as the analy-
sis for each. Accordingly, a difference in the correlation
between TVVF values and VEGF expression that was
evaluated using the rank sum test was identified for sur-
viving vs. deceased patients. For the surviving patients, a
significant positive correlation between TVVF and VEGF
scores was observed, which was not observed for the de-
ceased patients. Based on these results, we would then
ask, why do deceased patients, as opposed to surviving
patients, do not have TVVF values that positively corre-
late with VEGF expression?
It may be possible that the angiogenesis in these
neuroblastomas was not affected by the actions of VEGF
due to the influence of other factors that were activated
during hypoxia. Pathways induced by hypoxia, particu-
larly the hypoxia-inducible factor-1 (HIF-1) pathway, ha-
ve been shown to regulate the expression of a diverse
group of genes that promote tumor growth, and are in-
volved in tissue invasion, angiogenesis, cell proliferation,
glycolysis, and pH regulation41–45. Other reason for this
discrepancy is that in aggressive high risk neuroblasto-
ma, endothelial microvessels can originate from tumor
cells and have a high probability of being CD 34 negative.
This could be an explanation of low TVVF (based on
CD34 staining) in highly VEGF expressing tumors in de-
ceased patients. Therefore in future studies, it would be
important to label and analyze tumor vascular progeni-
tor cells. Some research indicates that they could possess
resistance to chemotherapy46.
Other studies have also found that angiogenesis cor-
relates with N-myc amplification, as well as poor out-
come, in patients with neuroblastoma. Correspondingly,
it has been hypothesized that N-myc may function in
part by promoting angiogenesis via VEGF3. Kang J et al.
(2008) pointed out the key role of PI3K/Akt/VEGF path-
way for angiogenesis in neuroblastoma and the impor-
tance of N-myc amplification in its regulation47.
Unfortunately, however, the N-myc status in this study
was unable to be determined for some patients due to our
inability to obtain DNA of sufficient quality for analysis.
However, we anticipate that this analysis will be com-
pleted on these samples in a future study.
Tumor lymphangiogenesis also affects the aggressive
behavior of malignant cells. Becker L et al. (2010) found
that together, upregulation of hemangiogenesis and lym-
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phangiogenesis activators (VEGF-A and VEGF-D, respec-
tively) and downregulation of hemangiogenesis and lym-
phangiogenesis inhibitors (VEGFR-1 and soluble form of
VEGFR-2, respectively) may represent cooperative me-
chanisms during neuroblastoma progression48. There-
fore analysis of lymphangiogenesis activators and inhibi-
tors in patients with high VEGF expression and low
TVVF could provide valuable insight.
Based on the results of this study, we would like to
emphasize the significant prognostic value associated
with an analysis of tumor vascularity in the context of
VEGF expression and its correlation with clinicopatho-
logical characteristics of high-risk neuroblastoma patients.
The multivariate analysis of survival confirmed the prog-
nostic significance of VEGF expression along with tumor
vascularity as a complex variable which was determined
as an independent predictor of overall survival.
For patients whose tumors exhibited high VEGF ex-
pression together with low vascularity (based on CD34
staining), these patients were more frequently associated
with advanced stage disease, and an unfavorable histol-
ogy, compared to all other patients.
When only advanced tumors were analyzed, with high
levels of VEGF expression and low tumor vascularity
evaluated as a complex variable, patient survival could
be predicted. In addition, the OSR for this group of pa-
tients was significantly lower, thereby identifying high
levels of VEGF expression in combination with TVVF
values 5% to be a prognostic marker independent of
clinical stage according to INSS. Furthermore, the sur-
vival of these high-risk patients was not significantly im-
proved with HSCT. These results suggest that this subset
of patients are candidates for new therapies, and the bio-
logical characteristics and mechanisms of resistance of
this tumor subtype need to be further investigated.
Conclusion
Analysis of tumor vascularity in relation to VEGF ex-
pression appears to be a good prognostic marker for
high-risk neuroblastoma patients, even as a factor inde-
pendent of clinical staging. When survival curves for
neuroblastoma patients with high VEGF expression and
low tumor vascularity were calculated with these factors
treated as a complex variable, OSRs were found to be re-
duced. In addition, the outcome for these patients was
not significantly improved by HSCT. Therefore, these pa-
tients may represent ideal candidates for receiving novel
therapies for the treatment of neuroblastoma.
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ODNOS IZME\U TUMORSKE VASKULARNOSTI I VASKULARNOG ENDOTELNOG ^IMBENIKA
RASTA KAO PROGNOSTI^KIH ^IMBENIKA KOD BOLESNIKA S NEUROBLASTOMOM
S A @ E T A K
Iako je utjecaj angiogeneze na tumorsku progresiju i lije~enje dosta istra`en, uloga angiogeneze i njeno prognosti~ko
zna~enje kod neuroblastoma u klini~koj praksi jo{ je nejasno. Cilj ovog rada bio je istra`iti da li kod neuroblastoma
tumorska vaskularnost u kombinaciji s ekspresijom vaskularnog endotelnog ~imbenika rasta (VEGF) predstavlja prog-
nosti~ki ~imbenik rizika. Pomo}u anti-CD34 i anti-VEGF antitijela u~injena je imunohistokemijska analiza tumorskog
tkiva pohranjenog u obliku parafinskih kocki kod 56 bolesnika s neuroblastomom. Tumorska vaskularnost procijenjena
je izra~unavanjem tumorske vaskularne volumne frakcije (TVVF), a ekspresija VEGF-a semikvantitativnim bodova-
njem. U~injena je odgovaraju}a statisti~ka obrada uklju~uju}i i multivarijantnu analizu pre`ivljenja. Tumorska vasku-
larnost utjecala je na pre`ivljenje bolesnika s visokom VEGF ekspresijom.Visoka VEGF ekspresija u kombinaciji s
TVVF 5% predstavljala je nezavisan prognosti~ki ~imbenik rizika (Coxova regresijska analiza, p-vrijednost=0,0041;
omjer mogu}nosti i 95% interval pouzdanosti =8,67 (1,99–37,69). Po prvi put otkrivena je skupina visoko rizi~nih bo-
lesnika ~iji su tumori imali istovremeno visoku VEGF ekspresiju i malu vaskularnost. Kod tih bolesnika zapa`en je
nizak postotak pre`ivljenja (37% naspram 92,5%) (p<0,0001). Oni nisu imali zna~ajno pobolj{anje pre`ivljenja niti
nakon transplantacije krvotvornih mati~nih stanica, te bi takvi pacijenti mogli biti kandidati za primjenu novih metoda
lije~enja. Navedeni rezultati upu}uju na va`nost me|usobnog odnosa tumorske vaskularnosti i VEGF-a, jer daje bolji
uvid u prognozu bolesnika s neuroblastomom.
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